Background illustration for clinical trials search

Triple Negative Breast Cancer Clinical Trials

Browse 2,256 triple negative breast cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1

Sample Collection and Tracking for the Developmental Therapeutics Clinic

for
Neoplasms, Lymphoma
Location: Bethesda MD
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18 - 70+

Code: NCT03269578

Recruiting

Registry for Intra-Operative Radiotherapy During Breast Conserving Surgery in Patients With Early Stage Breast Cancer

for
Early-stage Breast Cancer, Breast Carcinoma in Situ,
Location: Santa Monica CA
Sponsor: Saint John's Cancer Institute

Sex: All

Age: 18+

Code: NCT04603209

Recruiting

A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

for
Advanced Solid Tumors
Location: Boston MA, Toronto, Ann Arbor MI, Houston TX, Dallas TX,
Sponsor: LigaChem Biosciences, Inc.

Sex: All

Age: 18+

Code: NCT05941507

Phase 1, Phase 2, Recruiting

ATEMPT 2.0: Adjuvant T-DM1 vs TH

for
Breast Cancer, HER2-positive Breast Cancer
Location: Brewer ME, Scarborough ME, Weymouth MA, Danvers MA,
Sponsor: Dana-Farber Cancer Institute

Sex: All

Age: 18+

Code: NCT04893109

Phase 2, Recruiting

APBI: 27Gy in 5 Fractions for Early Breast Cancer

for
Breast Cancer
Location: Calgary
Sponsor: AHS Cancer Control Alberta

Sex: Female

Age: 50+

Code: NCT02681107

Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

Dietary Interventions in Cancer Patients Treated With Immune Checkpoint Inhibitors

for
Cancer
Location: Pittsburgh PA
Sponsor: University of Pittsburgh

Sex: All

Age: 18+

Code: NCT06475807

Recruiting

Contrast Enhanced Ultrasound Medical Imaging for Identifying Breast Masses

for
Breast Carcinoma
Location: Los Angeles CA
Sponsor: University of Southern California

Sex: Female

Age: 18+

Code: NCT06171607

Phase 1, Recruiting

Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors

for
Solid Tumor, Adult, Oncology
Location: Huntersville NC, Santa Monica CA
Sponsor: Trethera

Sex: All

Age: 18+

Code: NCT05055609

Phase 1, Recruiting

Modernizing Instructions to Improve Treatment Participation of Subjects During Their First Radiotherapy

for
Cancer
Location: Gainesville FL
Sponsor: University of Florida

Sex: All

Age: 18 - 70+

Code: NCT06246409

Recruiting

The ECOG-ACRIN SUPPORT Trial: Multilevel Intervention to Improve Diverse Enrollment in Cancer Clinical Trials

for
Cancer
Location: The Bronx NY, Scranton PA, Dickson City PA,
Sponsor: Eastern Cooperative Oncology Group

Sex: All

Age: 18+

Code: NCT06756607

Recruiting

Evaluation of Multi-Cancer Early Detection Testing in a High-Risk Military Population: The Sentinel Study

for
Cancer Diagnosis
Location: Boston MA
Sponsor: Dana-Farber Cancer Institute

Sex: All

Age: 45+

Code: NCT06523868

Recruiting

Autologous Adipose Cells Therapy

for
Hair Loss/Baldness, Wrinkle Appearance, Volume, Fine Lines,
Location: Lewes DE, Newark DE
Sponsor: CERM INC.

Sex: All

Age: 21 - 70+

Code: NCT06869252

Phase 1, Phase 2, Recruiting

Comprehensive Health Assessment for My Plan: Initial Implementation Study (CHAMP Implementation Study)

for
Cancer, Older Adults
Location: Toronto
Sponsor: University of Toronto

Sex: All

Age: 70+

Code: NCT06464471

Recruiting

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

for
Solid Tumor
Location: New York NY, Tampa FL, Augusta GA, Chicago IL,
Sponsor: Eisai Inc.

Sex: All

Age: 18+

Code: NCT04300556

Phase 1, Phase 2, Recruiting

Study of Lunresertib Alone or in Combination With RP-3500 or Zedoresertib (Debio 0123) in Patients With Advanced Solid Tumors

for
Advanced Solid Tumor
Location: Boston MA, Providence RI, New Haven CT,
Sponsor: Debiopharm International SA

Sex: All

Age: 12+

Code: NCT04855656

Phase 1, Recruiting

A Phase 1/2 Study of IAM1363 in HER2 Cancers

for
HER2 Mutation-Related Tumors, HER2, HER2-positive Breast Cancer,
Location: Boston MA, Lebanon NH, New York NY, New Brunswick NJ,
Sponsor: Iambic Therapeutics, Inc

Sex: All

Age: 18+

Code: NCT06253871

Phase 1, Phase 2, Recruiting

Ultrasound vs. Predetermined Distance Techniques for Paravertebral Nerve Block in Patients Having Breast Surgery

for
Mastectomy, Breast Neoplasms
Location: New Orleans LA
Sponsor: Ochsner Health System

Sex: Female

Age: 25 - 70+

Code: NCT01217593

Recruiting

A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors

for
Select Advanced Solid Tumors
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT06598371

Phase 1, Phase 2, Recruiting

Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial

for
Advanced Malignant Solid Neoplasm,
Location: Columbus OH
Sponsor: Yuanquan Yang

Sex: All

Age: 18+

Code: NCT06470971

Phase 2, Recruiting

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

for
Advanced Solid Tumors With KRAS G12C Mutations,
Location: Boston MA, Philadelphia PA, Fairfax VA, Detroit MI,
Sponsor: Frontier Medicines Corporation

Sex: All

Age: 18+

Code: NCT06244771

Phase 1, Phase 2, Recruiting

What is triple negative breast cancer?

Triple negative breast cancer, or TNBC, is breast cancer whose cells test negative for estrogen receptors, progesterone receptors, and excess HER2 protein, so hormone therapy and HER2 targeted drugs do not work against it. It tends to grow faster and is more common in women who have not gone through menopause, in Black women, and in people with an inherited BRCA1 mutation, so genetic testing is recommended for everyone diagnosed. In US data, five year relative survival is about 92 percent when it is found while localized, 67 percent with regional spread, and 15 percent once it has reached distant organs. Standard treatment for early stage disease is chemotherapy combined with immunotherapy before surgery, followed by more treatment after; metastatic disease is treated with chemotherapy, immunotherapy for PD-L1 positive tumors, and antibody drug conjugates. Other breast cancers are covered on our breast cancer clinical trials page.

Types of triple negative breast cancer clinical trials

Who can participate in triple negative breast cancer clinical trials?

Is triple negative breast cancer hereditary?

Stages of triple negative breast cancer, and why they matter for trials

How to enroll in a triple negative breast cancer clinical trial